A RANDOMIZED TRIAL OF CYCLOPHOSPHAMIDE WITH AND WITHOUT LOW-DOSE ALPHA-INTERFERON IN THE TREATMENT OF NEWLY DIAGNOSED MYELOMA

被引：7

作者：

AITCHISON, R ^{[1
]}

WILLIAMS, A ^{[1
]}

SCHEY, S ^{[1
]}

NEWLAND, AC ^{[1
]}

机构：

[1] ROYAL LONDON HOSP,DEPT HAEMATOL,LONDON E1 1BB,ENGLAND

来源：

LEUKEMIA & LYMPHOMA | 1993年 / 9卷 / 03期

关键词：

ALPHA-INTERFERON; CHEMOTHERAPY; MYELOMA;

D O I：

10.3109/10428199309147377

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The role of alpha-interferon (IFN) in initial treatment of multiple myeloma is controversial. We have conducted a trial of cyclophosphamide with and without low dose IFN in newly diagnosed myeloma. Thirty four patients, mean age 63 were all given cyclophosphamide 600mg/m2 IV every 21 days while 17 were randomised to also receive IFN at a dose equivalent to 6mU per week. In the IFN group 8/15 assessable patients (53%) had a greater than 50% reduction in paraprotein compared with 4/16 (25%) of controls (p < 0.05). However the median duration of response was the same in the two groups (IFN 8 months, controls 8.5 months). After a median follow up of 28 months there is no significant difference in survival. Toxicity including myelosuppression was commoner in the IFN group. These findings suggest that the addition of IFN to cyclophosphamide is not likely to offer major benefits in treating myeloma.

引用

页码：243 / 246

页数：4

共 18 条

[1]

Case D.C., Lee B.J., Clarkson B.D., Improved survival times in multiple myeloma treated with melphalan, prednisolone, cyclophosphamide, vincristine, BCNU: M2 protocol, Am. J. Med., 63, pp. 897-903, (1977)

[2]

Sporn J.R., McIntyre O.R., Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results, Semin. Oncol., 13, pp. 318-325, (1986)

[3]

Selby P.J., McElwain T., Nandi A.C., Et al., Multiple Myeloma treated with high dose intravenous melphalan, B. J. Haematol., 66, pp. 55-62, (1987)

[4]

Samson D., Newland A.C., Kearney J., Et al., Infusion of vincristine and doxorubicin with oral dex-amethasone as first line therapy for multiple myeloma, Lancet, II, pp. 882-885, (1989)

[5]

Gore M.E., Viner C., Meldrum M., Et al., Intensive treatment of multiple myeloma and criteria for complete remission, Lancet, II, pp. 879-881, (1989)

[6]

Barlogie B., Hall R., Zander A., Dickie K., Alexanian R., High dose Melphalan with Autologous transplantation for multiple myeloma, Blood, 67, pp. 1298-1301, (1986)

[7]

Gahrton G., Tura S., Belanger C., Et al., Allogeneic bone marrow transplantation in patients with multiple myeloma, Eur. J. Haematol., 43, pp. 182-185, (1989)

[8]

Kyle R.A., Multiple Myeloma a review of 869 cases, Mayo Clinic Proceedings, 50, pp. 29-40, (1975)

[9]

Costanzi J.J., Pollard R.B., The use of interferon in the treatment of multiple myeloma, The Interferon System-a current review to 1987, pp. 497-505, (1987)

[10]

Quesada J.R., Alexanian R., Hawkins M., Barlogie B., Et al., Treatment of multiple myeloma with recombinant alpha interferon, Blood, 67, pp. 275-278, (1986)

← 1 2 →